Rectal Adenocarcinoma — Trials

Rectal Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

187 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 52
Recruiting: 28
Ph III recruiting: 3
Growth YoY: —
Industry share: 2%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 39.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (32)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05610163	Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response(JANUS)	active not recruiting	Phase 2 / Phase 3	760	Alliance for Clinical Trials in OncologyOTHER	2	Sep 25, 2026	clinicaltrials
NCT02945566	Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?(STAR-TREC)	active not recruiting